David Vaughn, MD, Director of the Clinical Research Unit at the Abramson Cancer Center, offers a brief overview of recent considerations of the treatment of the genitourinary cancers as reported at ASCO, including the application of chemotherapy in metastatic prostate cancer, immunotherapy in the renal and bladder cancers and the question of whether adjuvant chemotherapy improves survival in high-risk bladder cancer.
Related Links
Published
April 22, 2015
Created by
BROADCASTMED